drugset
Drugs / PM8002
last change 2 days ago re-read 3 minutes ago

PM8002

also known as BNT327

Monoclonal antibody

Developed for
small cell lung carcinoma · hepatocellular carcinoma · non-small cell lung carcinoma · triple-negative breast carcinoma · cancer · colorectal cancer · neuroendocrine neoplasm
Investigated by
BioNTech SE · Shanghai Pulmonary Hospital, Shanghai, China

Trials 13

today NCT07133750 · Ph 2 NCT06837948 · Ph 2 NCT06584071 · Ph 1/2 NCT06616532 · Ph 3 NCT06419621 · Ph 3 NCT05756972 · Ph 2 NCT05844150 · Ph 2 NCT05879055 · Ph 2 NCT05918107 · Ph 2 NCT05918133 · Ph 1/2 NCT05879068 · Ph 2 NCT05864105 · Ph 2 NCT05918445 · Ph 1/2
202120222023202420252026202720282029203020312032
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/23 trials
Phase 1/2 NCT06584071 Dec 2024 → Oct 2026 expected hepatocellular carcinoma BioNTech SE Not yet recruiting No outcome recorded
Phase 1/2 NCT05918133 Jul 2022 → Oct 2026 expected triple-negative breast carcinoma BioNTech SE Active not recruiting No outcome recorded
Phase 1/2 NCT05918445 Mar 2021 → Nov 2025 overdue cancer BioNTech SE Recruiting No outcome recorded
Phase 28 trials
Phase 2 NCT07133750 Aug 2025 → Aug 2026 overdue colorectal cancer BioNTech SE Not yet recruiting No outcome recorded
Phase 2 NCT06837948 Feb 2025 → Dec 2031 expected non-small cell lung carcinoma Shanghai Pulmonary Hospital, Shanghai, China Not yet recruiting No outcome recorded
Phase 2 NCT05756972 Jun 2023 → Sep 2024 overdue non-small cell lung carcinoma BioNTech SE Active not recruiting No outcome recorded
Phase 2 NCT05844150 Jun 2023 → May 2024 overdue small cell lung carcinoma BioNTech SE Active not recruiting No outcome recorded
Phase 2 NCT05879055 May 2023 → Jan 2027 expected neuroendocrine neoplasm BioNTech SE Active not recruiting No outcome recorded
Phase 2 NCT05918107 Aug 2022 → Mar 2026 — BioNTech SE Completed No outcome recorded
Phase 2 NCT05879068 May 2022 → Apr 2025 overdue small cell lung carcinoma BioNTech SE Active not recruiting No outcome recorded
Phase 2 NCT05864105 Apr 2022 → Jul 2025 hepatocellular carcinoma BioNTech SE Completed No outcome recorded
Phase 32 trials
Phase 3 NCT06616532 Nov 2024 → Jan 2027 expected small cell lung carcinoma BioNTech SE Active not recruiting No outcome recorded
Phase 3 NCT06419621 Jun 2024 → Jul 2027 expected triple-negative breast carcinoma BioNTech SE Recruiting No outcome recorded

Press releases naming this drug 3 releases

DateIssuerRelease
2025-09-08 BioNTech SE First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity biontech.com ↗
2025-09-08 Bristol-Myers Squibb First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity bms.com ↗
2025-06-02 BioNTech SE BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types biontech.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as PM8002 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05844150 ↗
12

NCT05918445 ↗

NCT05918107 ↗

NCT06837948 ↗

NCT05756972 ↗

NCT07133750 ↗

NCT05879068 ↗

NCT05879055 ↗

NCT05918133 ↗

NCT06584071 ↗

NCT06419621 ↗

Show 2 more sources
Known as BNT327 “PM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF.” NCT07133750 ↗
Modality Monoclonal antibody “a Bispecific Antibody Targeting PD-L1 and VEGF-A” NCT05918445 ↗
Route Intravenous “IV infusion” NCT05756972 ↗